CA82529/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2002	1
2003	2
2005	1
2007	2
2008	2
2009	1
2011	2
2012	2
2014	1
2015	1
2024	0

1

B lymphocytes as effector cells in the immunotherapy of cancer.

Namm JP, Li Q, Lao X, Lubman DM, He J, Liu Y, Zhu J, Wei S, Chang AE. Namm JP, et al. J Surg Oncol. 2012 Mar 15;105(4):431-5. doi: 10.1002/jso.22093. Epub 2011 Sep 6. J Surg Oncol. 2012. PMID: 21898417 Free PMC article. Review.

2

Cancer stem cell vaccination confers significant antitumor immunity.

Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, Li M, Ginestier C, Wicha MS, Moyer JS, Prince ME, Xu Y, Zhang XL, Huang S, Chang AE, Li Q. Ning N, et al. Cancer Res. 2012 Apr 1;72(7):1853-64. doi: 10.1158/0008-5472.CAN-11-1400. Cancer Res. 2012. PMID: 22473314 Free PMC article.

3

Generation of a novel dendritic-cell vaccine using melanoma and squamous cancer stem cells.

Li Q, Lu L, Tao H, Xue C, Teitz-Tennenbaum S, Owen JH, Moyer JS, Prince ME, Chang AE, Wicha MS. Li Q, et al. J Vis Exp. 2014 Jan 6;(83):e50561. doi: 10.3791/50561. J Vis Exp. 2014. PMID: 24430104 Free PMC article.

4

Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.

Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S, Chang AE. Li Q, et al. Clin Cancer Res. 2011 Aug 1;17(15):4987-95. doi: 10.1158/1078-0432.CCR-11-0207. Epub 2011 Jun 20. Clin Cancer Res. 2011. PMID: 21690573 Free PMC article.

5

Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

Iuchi T, Teitz-Tennenbaum S, Huang J, Redman BG, Hughes SD, Li M, Jiang G, Chang AE, Li Q. Iuchi T, et al. Cancer Res. 2008 Jun 1;68(11):4431-41. doi: 10.1158/0008-5472.CAN-07-5530. Cancer Res. 2008. PMID: 18519706 Free PMC article.

6

4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.

Kroon HM, Li Q, Teitz-Tennenbaum S, Whitfield JR, Noone AM, Chang AE. Kroon HM, et al. J Immunother. 2007 May-Jun;30(4):406-16. doi: 10.1097/CJI.0b013e31802eecc6. J Immunother. 2007. PMID: 17457215

7

Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10.

Tao H, Lu L, Xia Y, Dai F, Wang Y, Bao Y, Lundy SK, Ito F, Pan Q, Zhang X, Zheng F, Shu G, Fang B, Jiang J, Xia J, Huang S, Li Q, Chang AE. Tao H, et al. Eur J Immunol. 2015 Apr;45(4):999-1009. doi: 10.1002/eji.201444625. Epub 2015 Jan 21. Eur J Immunol. 2015. PMID: 25545618 Free PMC article.

8

In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.

Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE. Li Q, et al. J Immunol. 2009 Sep 1;183(5):3195-203. doi: 10.4049/jimmunol.0803773. Epub 2009 Aug 10. J Immunol. 2009. PMID: 19667089 Free PMC article.

9

Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.

Ito F, Carr A, Svensson H, Yu J, Chang AE, Li Q. Ito F, et al. J Immunother. 2003 May-Jun;26(3):222-33. doi: 10.1097/00002371-200305000-00006. J Immunother. 2003. PMID: 12806276

10

Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.

Wei S, Shreiner AB, Takeshita N, Chen L, Zou W, Chang AE. Wei S, et al. Cancer Res. 2008 Jul 1;68(13):5432-8. doi: 10.1158/0008-5472.CAN-07-6598. Cancer Res. 2008. PMID: 18593946 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year